Literature DB >> 29488167

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.

Ayako Kamiunten1, Kotaro Shide1, Takuro Kameda1, Masaaki Sekine1, Yoko Kubuki1, Masafumi Ito2, Takanori Toyama3, Noriaki Kawano4, Kousuke Marutsuka4, Kouichi Maeda5, Masanori Takeuchi6, Hiroshi Kawano6, Seiichi Sato7, Junzo Ishizaki8, Keiichi Akizuki1, Yuki Tahira1, Haruko Shimoda1, Tomonori Hidaka1, Kiyoshi Yamashita4, Hitoshi Matsuoka6, Kazuya Shimoda9.   

Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with life-threatening thrombohemorrhagic events, and disease progression and development of non-hematological malignancies also reduce long-term survival. We retrospectively surveyed thrombohemorrhagic events and overall survival (OS) in 62 PV and 117 ET patients. The cumulative incidences of thrombohemorrhagic events in PV and ET patients were 11.3 and 10.3%, and the incidence rates were 2.42 and 1.85 per 100 person-years. The combined incidence rates of disease progression and development of non-hematological malignancies in PV and ET patients were 1.73 and 1.69 per 100 person-years. The incidence rates of thrombohemorrhagic events in our Japanese PV/ET patients were lower than those reported by most Western studies, but were comparable to those in the largest prospective observational study in ET patients. The combined incidence rates of disease progression and development of non-hematological malignancies were similar between Japanese and Western PV/ET patients. In ET patients, the conventional risk stratification model based on the presence of advanced age or history of thrombosis was useful to predict thrombosis risk, and both the conventional model and the International Prognostic Score of thrombosis in ET based on the above 2 risk factors plus increased leukocyte count could predict poor survival.

Entities:  

Keywords:  Essential thrombocythemia (ET); Polycythemia vera (PV); Prognosis; Thrombohemorrhagic events

Mesh:

Year:  2018        PMID: 29488167     DOI: 10.1007/s12185-018-2428-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  39 in total

1.  Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.

Authors:  Masahiro Okabe; Hiroki Yamaguchi; Kensuke Usuki; Yutaka Kobayashi; Eri Kawata; Junya Kuroda; Shinya Kimura; Kenji Tajika; Seiji Gomi; Nobuyoshi Arima; Sinichiro Mori; Shigeki Ito; Masayuki Koizumi; Yoshikazu Ito; Satoshi Wakita; Kunihito Arai; Tomoaki Kitano; Fumiko Kosaka; Kazuo Dan; Koiti Inokuchi
Journal:  Leuk Res       Date:  2015-11-10       Impact factor: 3.156

2.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Authors:  Malin Hultcrantz; Sigurdur Yngvi Kristinsson; Therese M-L Andersson; Ola Landgren; Sandra Eloranta; Asa Rangert Derolf; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

3.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

6.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

7.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

8.  JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).

Authors:  Noriko Usui
Journal:  Int J Hematol       Date:  2017-09-21       Impact factor: 2.490

Review 9.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

10.  Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Authors:  T Barbui; A M Vannucchi; V Buxhofer-Ausch; V De Stefano; S Betti; A Rambaldi; E Rumi; M Ruggeri; F Rodeghiero; M L Randi; I Bertozzi; H Gisslinger; G Finazzi; A Carobbio; J Thiele; F Passamonti; C Falcone; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-27       Impact factor: 11.037

View more
  5 in total

1.  Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masafumi Ito; Masaaki Sekine; Yoko Kubuki; Tomonori Hidaka; Keiichi Akizuki; Yuki Tahira; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Haruko Shimoda; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-07-09       Impact factor: 2.490

2.  Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.

Authors:  Yoko Edahiro; Tomoki Ito; Akihiko Gotoh; Mika Nakamae; Fumihiko Kimura; Michiaki Koike; Keita Kirito; Hideho Wada; Kensuke Usuki; Takayuki Tanaka; Takehiko Mori; Satoshi Wakita; Toshiki I Saito; Akiko Kada; Akiko M Saito; Kazuya Shimoda; Yuka Sugimoto; Toshiro Kurokawa; Akihiro Tomita; Yoshinori Hashimoto; Koichi Akashi; Itaru Matsumura; Katsuto Takenaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2022-07-09       Impact factor: 2.319

3.  Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.

Authors:  Yoko Edahiro; Kohshi Ohishi; Akihiko Gotoh; Katsuto Takenaka; Hirohiko Shibayama; Takayuki Shimizu; Kensuke Usuki; Kazuya Shimoda; Masafumi Ito; Scott A VanWart; Oleh Zagrijtschuk; Albert Qin; Hiroaki Kawase; Narihisa Miyachi; Toshiaki Sato; Norio Komatsu; Keita Kirito
Journal:  Int J Hematol       Date:  2022-04-16       Impact factor: 2.319

4.  Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study.

Authors:  Yoshinori Hashimoto; Tomoki Ito; Akihiko Gotoh; Mika Nakamae; Fumihiko Kimura; Michiaki Koike; Keita Kirito; Hideho Wada; Kensuke Usuki; Takayuki Tanaka; Takehiko Mori; Satoshi Wakita; Toshiki I Saito; Akiko Kada; Akiko M Saito; Kazuya Shimoda; Yuka Sugimoto; Toshiro Kurokawa; Akihiro Tomita; Yoko Edahiro; Koichi Akashi; Itaru Matsumura; Katsuto Takenaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2021-11-02       Impact factor: 2.490

5.  Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.

Authors:  Ik-Chan Song; Sang Hoon Yeon; Myung-Won Lee; Hyewon Ryu; Hyo-Jin Lee; Hwan-Jung Yun; Seon Young Kim; Deog-Yeon Jo
Journal:  Blood Res       Date:  2022-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.